ClinicalTrials.gg
CompletedNCT00174772Updated Feb 17, 2010

Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy and docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin in Lung Neoplasms, sponsored by Sanofi. Completed at 8 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-02-17.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 100 studies testing docetaxel in Lung Neoplasms — 1 open to participants now, 3 under way, 1 of them phase 3. Docetaxel · Lung Neoplasms.

Enrollment
28th of 90
72 · median 46
Started
2004
with 13 others
Phase 2
68 of 100
1 open now
Registered
37th of 100
by date
Lead sponsor
5 of 100
Sanofi

Among the 100 studies testing docetaxel in Lung Neoplasms, this one is the 28th largest by enrollment of the 90 interventional ones that give a count, is one of 14 that started in 2004, is one of 68 in phase 2, and was the 37th registered.

Lung Neoplasms

5,432 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

1 of the 100 studies testing docetaxel in Lung Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 996 Lung Neoplasms studies recruiting now, 685 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing docetaxel in Lung Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

  • To evaluate the toxicity/safety profile of docetaxel/cisplatin induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by consolidation docetaxel/cisplatin in patients with locally advanced unresectable NSCLC (stage IIIA- multiple cN2 or IIIB).

Secondary Objective:

  • To estimate efficacy parameters in overall response rate, progression free survival and 1 year survival for each of the two above mentioned arms.
03

Conditions studied

  • Lung Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma or a combination of these)
  • Patients must have a locoregionally advanced unresectable NSCLC

    • Stage IIIA with multiple level clinical N2 nodes (preferably with histological or cytological confirmation).
    • Patients with peripheral tumours of the lower lobe with contralateral upper mediastinal nodes at station N2 are excluded
    • Stage IIIB T4 or N3

      • In the T4 category, patients with pleural or pericardial effusion and multiple nodules in the same lobe are excluded.
      • Patients with T4 disease secondary to extensive and massive involvement of the great vessels are excluded.

Patients should be excluded when the expected risk of pulmonary toxicity is likely to be high, e.g. V20 in excess of 35%.

  • of at least 12 weeks.
  • 0 or 1.
  • Weight loss ≤ 10% within the last 3 months.
  • Laboratory requirements at entry (within 7 days before randomization):

    • Blood cell counts:

      • Absolute neutrophils ≥ 2.0 x 10\^9/L
      • ≥ 100 x 10\^9/L
      • ≥ 10 g/dl
    • Renal function:

      _Serum creatinine ≤1 x the (UNL). In case of borderline value of serum creatinine, the 24h should be ≥ 60 mL/min

    • Hepatic functions:

      • Serum ≤ 1 x UNL
      • ASAT and ALAT ≤ 2.5 x UNL
      • Alkaline phosphatase ≤ 5 x UNL.

Patients with ASAT and/or ALAT > 1.5 x UNL associated with alkaline phosphatase > 2.5 x UNL are not eligible for the study.

  • Lung function tests at entry:

    • : ≥ 50 % x Normal value
    • DLco: ≥ 50 % x Normal value.
  • Adequate cardiac function.
  • Patient with either measurable and/or non- (according to criteria).

Exclusion criteria

Exclusion criteria:

  • Diagnosis of small cell lung cancer
  • Pregnant or lactating women
  • Patients (male or female) with not implementing adequate measures
  • Prior systemic chemotherapy, immunotherapy, or biological therapy including or adjuvant treatment for NSCLC
  • Prior surgery for NSCLC, if less than 5 years from study
  • Prior radiotherapy for NSCLC
  • History of prior , except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least five years.
  • Symptomatic peripheral neuropathy Grade ≥ 2 except if due to trauma.
  • Other serious concomitant illness of medical conditions:

    • Congestive heart failure or angina pectoris except if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or arrhythmias.
    • History of significant neurologic or psychiatric disorders including dementia or seizures.
    • Active infection requiring IV antibiotics.
    • Active ulcer, unstable diabetes mellitus or other to therapy.
    • Superior vena cava syndrome contra-indicating hydration.
    • Preexisting pericardial effusion.
    • Preexisting symptomatic pleural effusion.
  • Significant gastrointestinal abnormalities, including requirement for intravenous nutrition, active peptic ulcer disease, prior surgical procedures affecting absorption.
  • Distant .
  • Concurrent treatment with any other experimental anti-cancer drugs.
  • Concomitant or within 4-week period administration of any other experimental drug under investigation.
  • Significant ophthalmologic abnormalities.
  • Moderate to severe dermatitis.
  • to docetaxel or any of its .
  • Concomitant use of phenytoin, carbamazepin, barbiturates, or rifampicin.
  • Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.
  • Patient unlikely to comply with protocol, i.e., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    B

    Concurrent chemoradiotherapy followed by consolidation chemotherapy

    Drug: docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin

  • Experimental
    A

    Induction chemotherapy followed by concurrent chemoradiotherapy

    Drug: docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy

Interventions

  • Drugdocetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy

    docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy

  • Drugdocetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin

    Drug pages: Docetaxel · Cisplatin

    docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.

06

What researchers measure

Primary outcomes

  1. anti-tumor activity including overall response rate

    Time frame: assessed at the end of the full course of treatment period

Secondary outcomes

  1. all treatment related acute and chronic toxicity assessed according to the NCI-CTC scale

    Time frame: throughout the study

  2. other adverse events not reported in the NCI-CTI scale

    Time frame: throughout the study

  3. hematological and non-hematological toxicities

    Time frame: reported for all grades observed during each cycle

07

Study locations

8 sites
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey
  • Sanofi-Aventis Administrative Office
    Guilford, United Kingdom
08

References and documents

Publications

  • van Sornsen de Koste JR, Senan S, Underberg RW, Oei SS, Elshove D, Slotman BJ, Lagerwaard FJ. Use of CD-ROM-based tool for analyzing contouring variations in involved-field radiotherapy for Stage III NSCLC. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):334-9. doi: 10.1016/j.ijrobp.2005.02.016. PubMed 16168828 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 15, 2005
Start
Mar 2004
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Last update
Feb 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00174772
Lead sponsor
Sanofi
First posted
Sep 15, 2005
Start date
Mar 2004
Primary completion
Feb 2009
Completion
Feb 2009
Last update
Feb 17, 2010

Study contacts

Jean-Philippe Aussel
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Cisplatin

Start the discussion